albumin conjugate raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-10-16 and is reviewed periodically as new material appears.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
| Property | Value | Notes |
|---|---|---|
| Primary target | GHRH receptor | G-protein-coupled receptor on pituitary somatotrophs |
| Half-life, long-acting form | Several days | Extended by covalent albumin binding |
| Half-life, short form | About 30 minutes | Cleared rapidly by peptidases and kidneys |
| Route in studies | Subcutaneous injection | Used in the published human trials |
| Main measured effect | Rise in GH and IGF-1 | Surrogate markers rather than clinical endpoints |
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
=== Nuclear fission === The longest-lived and most abundant isotope, 231Pa, can fission from fast neutrons exceeding ~1 MeV. 233Pa, the other isotope of protactinium produced in nuclear reactors, also has a fission threshold of 1 MeV.
Montirelin (also known as CG-3703 or NS-3) is a synthetic analogue of thyrotropin-releasing hormone (TRH), designed to enhance central nervous system stimulation with greater potency and duration than natural TRH. Montirelin binds to TRH receptors in the brain, stimulating the release of thyrotropin (TSH) and prolactin. It exhibits sustained receptor occupancy and a counter-clockwise hysteresis between plasma concentration and receptor binding, suggesting prolonged CNS activity. Montirelin has demonstrated efficacy in animal models for:
Aquileia was founded as a colony by the Romans in 180/181 BC along the Natiso River, on land south of the Julian Alps but about 13 kilometres (8 mi) north of the lagoons. The colony served as a strategic frontier fortress at the north-east corner of transpadane Italy (on the far side of the Po river) and was intended to protect the Veneti, faithful allies of Rome during the invasion of Hannibal in the Second Punic War and during the Illyrian Wars. The colony would serve as a citadel to check the advance into Cisalpine Gaul of other warlike peoples, such as the hostile Carni to the northeast in what is now Carnia and Histri tribes to the southeast in what is now Istria. In fact, the site chosen for Aquileia was about 6 km (3.7 mi) from where an estimated 12,000 Celtic Taurisci had attempted to settle in 183 BC. However, since the thirteenth century BC, the site, on the river and at the head of the Adriatic, had also been of commercial importance as the end of the Baltic amber (sucinum) trade. It is, therefore, theoretically not unlikely that Aquileia had been a Gallic oppidum even before the coming of the Romans. However, few Celtic artefacts have been discovered from 500 BC to the Roman arrival. The colony was established with Latin Rights by the triumvirate of Publius Cornelius Scipio Nasica, Caius Flaminius, and Lucius Manlius Acidinus, two of whom were of consular and one of praetorian rank. Each of the men had first-hand knowledge of Cisalpine Gaul. Nasica had conquered the Boii in 191.
== Early life and education == Leena Maria Hämäläinen (later Ala-Kokko) was born on 21 July 1961 in Oulu, Finland. She graduated from high school at Oulun Lyseon lukio in 1980. She continued her studies at the University of Oulu, from which she obtained her licentiate in medicine in 1986, before gaining her PhD in medicine the following year. In her thesis, Ala-Kokko studied the overproduction of collagen in the skin and liver. Ala-Kokko gained research experience in professor Kari Kivirikko's collagen research group.
The alactic anaerobic system, which consists of high energy phosphates, adenosine triphosphate, and creatine phosphate; and The lactic anaerobic system, which features anaerobic glycolysis. High energy phosphates are stored in limited quantities within muscle cells. Anaerobic glycolysis exclusively uses glucose (and glycogen) as a fuel in the absence of oxygen, or more specifically, when ATP is needed at rates that exceed those provided by aerobic metabolism. The consequence of such rapid glucose breakdown is the formation of lactic acid (or more appropriately, its conjugate base lactate at biological pH levels). Physical activities that last up to about thirty seconds rely primarily on the former ATP-CP phosphagen system. Beyond this time, both aerobic and anaerobic glycolysis-based metabolic systems are used. The by-product of anaerobic glycolysis—lactate—has traditionally been thought to be detrimental to muscle function. However, this appears likely only when lactate levels are very high. Elevated lactate levels are only one of many changes that occur within and around muscle cells during intense exercise that can lead to fatigue. Fatigue, which is muscle failure, is a complex subject that depends on more than just changes to lactate concentration. Energy availability, oxygen delivery, perception to pain, and other psychological factors all contribute to muscular fatigue. Elevated muscle and blood lactate concentrations are a natural consequence of any physical exertion. The effectiveness of anaerobic activity can be improved through training.
Sources: en.wikipedia.org
=== 18th century === The technical knowledge for making hydraulic cement was formalized by French and British engineers in the 18th century. John Smeaton made an important contribution to the development of cements while planning the construction of the third Eddystone Lighthouse (1755–59) in the English Channel now known as Smeaton's Tower. He needed a hydraulic mortar that would set and develop some strength in the twelve-hour period between successive high tides. He performed experiments with combinations of different limestones and additives including trass and pozzolanas and did exhaustive market research on the available hydraulic limes, visiting their production sites, and noted that the "hydraulicity" of the lime was directly related to the clay content of the limestone used to make it. Smeaton was a civil engineer by profession, and took the idea no further. In the South Atlantic seaboard of the United States, tabby relying on the oyster-shell middens of earlier Native American populations was used in house construction from the 1730s to the 1860s. In Britain particularly, good quality building stone became ever more expensive during a period of rapid growth, and it became a common practice to construct prestige buildings from the new industrial bricks, and to finish them with a stucco to imitate stone. Hydraulic limes were favored for this, but the need for a fast set time encouraged the development of new cements. Most famous was Parker's "Roman cement". This was developed by James Parker in the 1780s, and finally patented in 1796.
=== Organic compound peptide-based batteries === StoreDot reported in 2014 to have developed organic-compound peptide-based smartphone batteries capable of being fully charged within 30 seconds. The company said its 30-second-charging organic-compound-based battery would be commercially available for smartphones by 2016. The company announced its 5-minutes-to-full-charge organic batteries will be available for 300-mile-range electric vehicles and aerial drones by 2020. The company acknowledged in 2015 that its claims regarding its organic batteries have not been scientifically peer-reviewed.
18 July – Starmer pledges £84m in funding for education, employment and humanitarian projects in Africa and the Middle East designed to stop illegal migration "at source". 19 July – Ukrainian president Volodymyr Zelenskyy visits Downing Street and addresses the cabinet, becoming the first foreign leader to address a British cabinet since 1997, and urges Keir Starmer to "show your leadership" by helping to remove restrictions on the use of weapons supplied to Ukraine. Sunak makes junior appointments to his shadow frontbench team, including some newly elected MPs, meaning 51 of the 121 Conservative MPs in parliament now have shadow ministerial posts. Foreign Secretary David Lammy confirms the UK will resume funding UNRWA, the UN's agency for Palestinian refugees. Shadow Secretary of State for Health and Social Care Victoria Atkins is criticised by House of Commons Deputy Speaker Christopher Chope for her behaviour during a parliamentary debate after she loudly interrupted Steve Reed, the Secretary of State for Environment, Food and Rural Affairs as he addressed the House. 20 July – Figures produced by the Institute for Fiscal Studies suggest the UK government would need to spend an extra £3bn to implement a 5.5% pay rise for teaching and NHS staff. July 2024 Welsh Labour leadership election: Welsh Labour officials agree a timeline for the election, with a new leader to be in place on 14 September. Nominations open for candidates entering the leadership contest.
Polonium is a chemical element; it has symbol Po and atomic number 84. A rare and highly radioactive metal (although sometimes classified as a metalloid) with no stable isotopes, polonium is a chalcogen and chemically similar to selenium and tellurium, though its metallic character resembles that of its horizontal neighbours in the periodic table: thallium, lead, and bismuth. Due to the short half-life of all its isotopes, its natural occurrence is limited to tiny traces of the fleeting polonium-210 (with a half-life of 138 days) in uranium ores, as it is the penultimate daughter of natural uranium-238. Though two longer-lived isotopes exist (polonium-209 with a half-life of 124 years and polonium-208 with a half-life of 2.898 years), they are much more difficult to produce. Today, polonium is usually produced in milligram quantities by the neutron irradiation of bismuth. Due to its intense radioactivity, which results in the radiolysis of chemical bonds and radioactive self-heating, its chemistry has mostly been investigated on the trace scale only. Polonium was discovered on 18 August 1898 by Marie Skłodowska-Curie and Pierre Curie, when it was extracted from the uranium ore pitchblende and identified solely by its strong radioactivity: it was the first element to be discovered in this way. Polonium was named after Marie Skłodowska-Curie's homeland of Poland, which at the time was partitioned between three countries.
Sources: en.wikipedia.org
It binds the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Receptor activation raises cyclic AMP and promotes release of stored growth hormone granules. Because the peptide persists longer than natural releasing hormone, stimulation is prolonged rather than brief.
The drug affinity complex links the peptide to serum albumin through a covalent bond. The conjugate is too large to be filtered quickly by the kidneys and is shielded from enzymatic breakdown. This extends the apparent half-life from roughly minutes to several days.
Long-term safety and any clinical benefit are unestablished. Published human data cover small groups over limited periods and focus on hormone levels rather than health outcomes. Whether prolonged elevation of growth hormone and insulin-like growth factor 1 is beneficial or harmful is an open question.
The two share the same 29-amino-acid backbone. CJC-1295 carries an additional albumin-binding moiety that markedly extends its residence time in circulation, while the form without that moiety clears faster. Literature sometimes applies the name loosely to either variant.